<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824083</url>
  </required_header>
  <id_info>
    <org_study_id>01ER0807</org_study_id>
    <nct_id>NCT00824083</nct_id>
  </id_info>
  <brief_title>Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment</brief_title>
  <official_title>Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the functional outcome, quality of life and late
      sequelae in a representative sample of 600 long-term survivors of Ewing sarcoma and to build
      a unique clinical and functional data pool of the underlying cohort of 3000 Ewing sarcoma
      patients with a follow-up of 3 decades.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial objective: As survival rates of bone sarcoma patients have been raised owing to
      improved treatment strategies the focus of investigations is now on the medical, social, and
      economic sequelae of intensive multimodal treatment. This study aims to assess the functional
      outcome, quality of life and late sequelae in a representative sample of long-term survivors
      of Ewing sarcoma. The data recorded combined with standardized treatment data covering a
      30-year period will produce a data pool that is unique for its magnitude and will be used for
      the development of guidelines for further improvements of future bone sarcoma treatment.

      Working plan: The working plan provides for the assessment of functional outcome and quality
      of life by means of validated tools (TESS, SF36, PEDQOL) and objectively measuring daily
      activity patterns by using the Step Activity Monitor (SAM) in 600 long-term Ewing sarcoma
      survivors and a control group of 300 matched healthy subjects. Information on sarcoma
      treatment and follow-up is obtained by re-structuring and complementing the database of the
      relevant patient cohort (n=3000) from four consecutive nationwide and international clinical
      trials between 1980 and 2008. Procedures of local treatment will be evaluated regarding
      functional outcome, quality of life, and survival probability and prognostic factors
      predicting long-term outcome will be identified.

      Exploitation of results: The results will be presented at scientific meetings and will be
      published in international journals. Guidelines will be developed regarding improvements in
      the treatment, rehabilitation, and social integration of bone sarcoma patients to be utilized
      in guiding patients and in the decision process of medical professionals regarding their
      treatment. In the long run, the evidence based guidelines on treatment and follow-up are to
      be transferred into the health system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>physical activity (SAM: step-activity-monitor)</measure>
    <time_frame>3-30years after primary diagnosis of Ewing sarcoma</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>health-related quality of life (SF36, PEDQOL)</measure>
    <time_frame>3-30years after primary diagnosis of Ewing sarcoma</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional status (TESS)</measure>
    <time_frame>3-30years after primary diagnosis of Ewing sarcoma</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>psychological status (HADS, BIS-BAS)</measure>
    <time_frame>3-30years after primary diagnosis of Ewing sarcoma</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">950</enrollment>
  <condition>Sarcoma, Ewing's</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>sarcoma survivors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>healthy subjects</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Ewing sarcoma survivors and 1:2 matched control group of healthy subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CESS81/CESS86/EICESS92/EURO-E.W.I.N.G.99 trials participants of the German Society of
             Pediatric Hematology and Oncology (GPOH)

        Exclusion Criteria:

          -  no complete remission (CR)

          -  any kind of paralysis

          -  &lt;3y after diagnosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Ranft, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Muenster</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heribert Jürgens, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Muenster</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatric Hematology and Oncology, University Children's Hospital</name>
      <address>
        <city>Muenster</city>
        <state>North Rhine Westphalia</state>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Motion Analysis Lab, Orthopedic Department, University Hospital</name>
      <address>
        <city>Münster</city>
        <state>North Rhine Westphalia</state>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Brandes M, Schomaker R, Möllenhoff G, Rosenbaum D. Quantity versus quality of gait and quality of life in patients with osteoarthritis. Gait Posture. 2008 Jul;28(1):74-9. Epub 2007 Nov 28.</citation>
    <PMID>18054233</PMID>
  </reference>
  <reference>
    <citation>Gerber LH, Hoffman K, Chaudhry U, Augustine E, Parks R, Bernad M, Mackall C, Steinberg S, Mansky P. Functional outcomes and life satisfaction in long-term survivors of pediatric sarcomas. Arch Phys Med Rehabil. 2006 Dec;87(12):1611-7.</citation>
    <PMID>17141641</PMID>
  </reference>
  <reference>
    <citation>Hoffmann C, Gosheger G, Gebert C, Jürgens H, Winkelmann W. Functional results and quality of life after treatment of pelvic sarcomas involving the acetabulum. J Bone Joint Surg Am. 2006 Mar;88(3):575-82.</citation>
    <PMID>16510825</PMID>
  </reference>
  <reference>
    <citation>McDonald CM, Widman L, Abresch RT, Walsh SA, Walsh DD. Utility of a step activity monitor for the measurement of daily ambulatory activity in children. Arch Phys Med Rehabil. 2005 Apr;86(4):793-801.</citation>
    <PMID>15827934</PMID>
  </reference>
  <reference>
    <citation>Nagarajan R, Neglia JP, Clohisy DR, Robison LL. Limb salvage and amputation in survivors of pediatric lower-extremity bone tumors: what are the long-term implications? J Clin Oncol. 2002 Nov 15;20(22):4493-501. Review.</citation>
    <PMID>12431974</PMID>
  </reference>
  <reference>
    <citation>Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Köhler G, Poremba C, Zoubek A, Ladenstein R, van den Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jürgens H; European Intergroup Cooperative Ewing's Sarcoma Study-92. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008 Sep 20;26(27):4385-93. doi: 10.1200/JCO.2008.16.5720.</citation>
    <PMID>18802150</PMID>
  </reference>
  <reference>
    <citation>Pieper S, Ranft A, Braun-Munzinger G, Jurgens H, Paulussen M, Dirksen U. Ewing's tumors over the age of 40: a retrospective analysis of 47 patients treated according to the International Clinical Trials EICESS 92 and EURO-E.W.I.N.G. 99. Onkologie. 2008 Dec;31(12):657-63. doi: 10.1159/000165361. Epub 2008 Nov 20.</citation>
    <PMID>19060503</PMID>
  </reference>
  <reference>
    <citation>Rödl RW, Hoffmann C, Gosheger G, Leidinger B, Jürgens H, Winkelmann W. Ewing's sarcoma of the pelvis: combined surgery and radiotherapy treatment. J Surg Oncol. 2003 Jul;83(3):154-60.</citation>
    <PMID>12827683</PMID>
  </reference>
  <reference>
    <citation>Rosenbaum D, Brandes M, Hardes J, Gosheger G, Rödl R. Physical activity levels after limb salvage surgery are not related to clinical scores-objective activity assessment in 22 patients after malignant bone tumor treatment with modular prostheses. J Surg Oncol. 2008 Aug 1;98(2):97-100. doi: 10.1002/jso.21091.</citation>
    <PMID>18521841</PMID>
  </reference>
  <reference>
    <citation>Schuck A, Ahrens S, Paulussen M, Kuhlen M, Könemann S, Rübe C, Winkelmann W, Kotz R, Dunst J, Willich N, Jürgens H. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):168-77.</citation>
    <PMID>12504050</PMID>
  </reference>
  <reference>
    <citation>Song KM, Bjornson KF, Cappello T, Coleman K. Use of the StepWatch activity monitor for characterization of normal activity levels of children. J Pediatr Orthop. 2006 Mar-Apr;26(2):245-9.</citation>
    <PMID>16557143</PMID>
  </reference>
  <reference>
    <citation>Weddington WW. Psychological outcomes in survivors of extremity sarcomas following amputation or limb-sparing surgery. Cancer Treat Res. 1991;56:53-60. Review.</citation>
    <PMID>1681879</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <last_update_submitted>April 27, 2016</last_update_submitted>
  <last_update_submitted_qc>April 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone tumors</keyword>
  <keyword>long-term function</keyword>
  <keyword>daily activity</keyword>
  <keyword>late sequelae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

